Therapeutic Area

Small Molecule

Therapeutic area intelligence for Small Molecule with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 2

Companies

Deciphera Pharmaceuticals, LLC →

Merck →

Assets

Vimseltinib →

Welireg →

Recent signals(4)

RegulatoryJune 20, 2026

FDA Grants Priority Review for Welireg Supplement from Merck

The FDA has granted priority review for the supplemental NDA for Welireg (belzutifan) submitted by Merck.

ClinicalJune 18, 2026

Deciphera's Vimseltinib Study Evaluates Interaction with Oral Contraceptives

A clinical trial is underway to assess how vimseltinib affects the pharmacokinetics of a combined oral contraceptive.

RegulatoryJune 18, 2026

FDA Grants Priority Review for Welireg Supplement NDA215383

The FDA has granted priority review for the supplemental NDA for Welireg (belzutifan) submitted by Merck Sharp Dohme.

StrategyJune 17, 2026

Merck's Acquisition of Terns Pharmaceuticals Advances as HSR Waiting Period Expires

Merck's acquisition of Terns Pharmaceuticals progresses as the HSR waiting period has expired, allowing the tender offer to move forward.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.